UBS Group Cuts Zoetis (NYSE:ZTS) Price Target to $141.00

Zoetis (NYSE:ZTS) had its price target reduced by UBS Group from $158.00 to $141.00 in a report issued on Wednesday,Benzinga reports. They currently have a neutral rating on the stock.

Other research analysts have also issued reports about the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Argus reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Stifel Nicolaus set a $140.00 target price on Zoetis in a report on Tuesday. Piper Sandler raised their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $191.00.

Zoetis Price Performance

ZTS opened at $120.20 on Wednesday. Zoetis has a 1 year low of $117.26 and a 1 year high of $181.85. The company’s 50 day simple moving average is $144.21 and its 200 day simple moving average is $152.60. The stock has a market capitalization of $53.27 billion, a PE ratio of 20.69, a P/E/G ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts expect that Zoetis will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.7%. Zoetis’s payout ratio is 33.67%.

Institutional Trading of Zoetis

A number of hedge funds have recently made changes to their positions in the company. Savvy Advisors Inc. raised its holdings in shares of Zoetis by 54.0% during the second quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after acquiring an additional 1,114 shares in the last quarter. Sound Income Strategies LLC grew its stake in Zoetis by 54.3% in the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after purchasing an additional 152 shares in the last quarter. Canoe Financial LP increased its position in Zoetis by 859.0% in the 2nd quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock worth $2,085,000 after purchasing an additional 11,975 shares during the last quarter. Strs Ohio purchased a new stake in shares of Zoetis during the 1st quarter worth about $22,891,000. Finally, Soros Capital Management LLC raised its stake in shares of Zoetis by 32.0% during the 1st quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock worth $2,872,000 after purchasing an additional 4,230 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.